Filing Details

Accession Number:
0001126234-13-000083
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-10 17:48:50
Reporting Period:
2013-05-09
Filing Date:
2013-05-10
Accepted Time:
2013-05-10 17:48:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1126234 Newlink Genetics Corp (NLNK) Pharmaceutical Preparations (2834) 421491350
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1512113 Jr. J. Charles Link C/O Newlink Genetics Corp.
2503 South Loop Dr., Suite 5100
Ames IA 50010
Chairman Of The Board And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2013-05-09 40,000 $14.58 1,083,487 No 4 S Direct
Common Stock Disposition 2013-05-10 35,000 $14.96 1,048,487 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Indirect By Spouse
Common Stock 139 Indirect By Spouse's IRA
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 11/14/2012.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.50 to $14.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote 2 to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.70 to $15.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote 3 to this Form 4.